Cerebrolysin

Also known as: cerebral peptides, porcine brain peptide mixture

Evidence Tier Cmedium riskadvancednot approved

Porcine neuropeptide mixture used in some international stroke and cognition programs, but not FDA-approved.

Clinical Stage

This is a clinical-stage therapeutic, not a typical consumer RUO product. Information is provided for educational context about ongoing clinical research.

Overview

Cerebrolysin is not a single peptide but a porcine-derived neuropeptide mixture used in some countries for stroke and cognitive recovery. Evidence quality is mixed and product standardization is harder to assess than for single-molecule peptides. It should be treated as an advanced neurorecovery compound with limited relevance to casual nootropic use.

Research Details

Mechanism of Action

Proposed neurotrophic and neuroprotective signaling from a peptide/amino-acid mixture; exact active components remain poorly defined.

Study Dose Range

Clinical programs often use 5 mL to 30 mL IV daily over 10 to 20 days depending on indication.

Administration Routes

intravenous, intramuscular

Onset / Timeline

Clinical outcomes are tracked over days to weeks in stroke or cognition programs.

Expected Effects

Possible neurorecovery or cognitive-support effects in select clinical settings, though evidence quality is heterogeneous.

Adverse Effects

Headache, fever, nausea, restlessness, injection reactions, and rare hypersensitivity are reported.

Contraindications

Use caution in porcine-protein sensitivity and where product provenance cannot be established.

Interaction Notes

No strong interaction map; combining with other CNS-active research compounds increases interpretation difficulty.

Related Goals

Tissue Repair & RecoveryCognitive & Neuroprotection

Known Interactions

caution with Semax

Both are CNS-active experimental agents. Combination claims are stronger than the human safety evidence.

caution with Selank

Neuroactive stack with limited direct human interaction evidence.

caution with NSI-189

Two experimental neurotrophic-style agents with little human combination data.

Available From

No vendors currently listed for this peptide.

Frequently Compared

BPC-157

Preclinical cytoprotective peptide studied for tissue repair and GI protection in animal models.

Tier C

Thymosin Beta-4

Actin-sequestering peptide with clinical data in ophthalmic wound healing and preclinical tissue repair.

Tier B-C

TB-500

Marketed thymosin beta-4 fragment (LKKTETQ actin-binding motif) studied for soft-tissue repair in preclinical models.

Tier C

Semax

ACTH fragment analogue with preclinical neurotrophic signaling and limited clinical stroke/cognition data.

Tier B-C

Information provided for educational and research reference only. Not medical advice. Not for diagnosing, treating, curing, or preventing disease. Products referenced are labeled Research Use Only (RUO) by vendors; not for human or veterinary use.